|
Nyxoah SA (Nyxoah), a medical technology company that develops breakthrough treatment alternatives for obstructive sleep apnoea (OSA) through neuromodulation, announced the commercial launch of its Genio system in England, marked by the first successful implants performed at University College London Hospitals (UCLH).
Genio is now covered under the NHS Specialised Services Devices Programme (SSDP), enabling access to innovative therapies through specialized centres of excellence.
The first two patients were successfully implanted by Ryan Chin Taw Cheong, consultant ENT and sleep surgeon at UCLH. Commenting on the milestone, Cheong said: “We are proud to be the first hospital in the UK to offer Genio to our OSA patients. Genio is a groundbreaking, clinically proven therapy that addresses the unmet needs of individuals suffering from obstructive sleep apnoea.”
Olivier Taelman, CEO of Nyxoah, added: “Today represents an important milestone for Nyxoah as we introduce our Genio neurostimulation solution to treat obstructive sleep apnoea in England. Congratulations to Cheong and his team on this remarkable achievement. We look forward to expanding our collaboration with UCLH and other leading hospitals in England as we continue our mission to make sleep simple for OSA patients.”
Nyxoah is reinventing sleep for the billion people that suffer from obstructive sleep apnoea (OSA). The company is a medical technology company that develops breakthrough treatment alternatives for OSA through neuromodulation.
|